Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
Thursday December 20, 6:43 am ET
http://biz.yahoo.com/prnews/071220/neth037.html?.v=35
BRANFORD, Conn., Dec. 20 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced the appointment of Sean Cassidy, as Vice President and Chief Financial Officer effective January 1, 2008. CuraGen also announced today that David M. Wurzer will step down from his position effective January 1, 2008 to pursue other opportunities, but will remain with the Company through March 2008, as an advisor to the Company.
"We are pleased to welcome Sean to the CuraGen team," commented Timothy Shannon, President and Chief Executive Officer. "We believe that Sean's accounting and financial expertise in the life sciences sector, combined with his historical knowledge of CuraGen, will be beneficial as we advance our development pipeline towards commercialization."
Dr. Shannon further commented, "On behalf of the entire board and employees of CuraGen, I would like to thank Dave Wurzer for his more than 10 years of service to CuraGen during which he made substantial contributions across the organization. Dave will continue to work with CuraGen over the next few months to ensure a smooth and effective transition."
Previously, Mr. Cassidy served as Corporate Controller of 454 Life Sciences Corporation (454) since September 2002. Mr. Cassidy joined 454 when it was a development stage company and supported its growth into a successful commercial entity. During this time, Mr. Cassidy assisted 454 in a private round of financing in 2003, entering into a comprehensive License, Supply and Distribution Agreement with Roche Applied Science in 2005 and in the acquisition of 454 by Roche Applied Science in 2007. Prior to joining 454, Mr. Cassidy served as Manager of Financial Planning at CuraGen Corporation from August 2001 to September 2002. Mr. Cassidy also spent over eight years at Deloitte & Touche LLP's Hartford office in the audit practice. During this time Mr. Cassidy served both public and private companies in various industries; advising these clients on public and private securities offerings, mergers and acquisition due diligence reviews and annual and quarterly reporting requirements under the Securities and Exchange Commission's rules and regulations.
Mr. Cassidy earned both his Master of Business Administration degree and his Bachelor of Science in Accounting from the University of Connecticut in 2000 and 1992, respectively. Mr. Cassidy is a certified public accountant in the State of Connecticut.
About CuraGen
CuraGen Corporation (Nasdaq: CRGN - News) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com.
Safe Harbor
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the benefits to be achieved as a result of Mr. Cassidy's hiring may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific, regulatory or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CRGN-G
Contacts:
Glenn Schulman, PharmD
Director of Investor Relations
gschulman@curagen.com
(888) 436-6642
CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
Wednesday December 19, 6:30 am ET
BRANFORD, Conn., Dec. 19 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous belinostat, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of patients with previously-treated thymoma and thymic carcinoma. This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for belinostat.
http://biz.yahoo.com/prnews/071219/new001.html?.v=26
Thanks for the heads up surf, been gone all day, just got back in time to grab some. haven't checked out vnda yet.
CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
Monday December 10, 5:00 pm ET
- Conference call to be hosted on Tuesday, December 11th at 9:00 a.m. Eastern time -
- Encouraging clinical results presented at ASH from the ongoing Phase II trial in T-cell lymphomas -
- Positive End-of-Phase II meeting held with the FDA for belinostat in PTCL -
BRANFORD, Conn., Dec. 10 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated clinical trial results on intravenous belinostat for the treatment of T-cell lymphomas were reported today at the 2007 American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, GA.
CuraGen and TopoTarget also reported today that the preliminary peripheral T-cell lymphoma (PTCL) results from this ongoing trial were submitted to the U.S. Food and Drug Administration (FDA) as part of an End-of-Phase II meeting held on November 29, 2007 to review the development of intravenous belinostat for the treatment of PTCL. Based on this meeting with the FDA, CuraGen plans to submit a clinical trial protocol to the FDA under a Special Protocol Assessment (SPA) and anticipates initiating a registrational clinical trial for PTCL during the second half of 2008.
"We are very encouraged by the overall activity, the complete responses and the duration of responses we have observed with belinostat for patients with advanced T-cell lymphomas. We are opening additional U.S. and international sites to enhance enrollment in the ongoing Phase II study in order to increase our understanding of the activity in T-cell lymphomas and to gear up our operations for the registrational study in PTCL, which we plan to initiate in the second half of 2008," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen. "We are also excited about the previously reported activity of belinostat in combination with carboplatin and paclitaxel for the treatment of recurrent ovarian cancer. We are working with our advisors to define the next steps in this indication, and look forward to presenting additional Phase II data and clinical development plans in 2008."
http://biz.yahoo.com/prnews/071210/nem109a.html?.v=1
I have been buying back some CRGN around $1, it should go with the rest of rally. This is the first time in months that I have no short hedges(rally on)
surf
Hello surf, Any current thoughts on crgn? It nears the dollar level once again.
Take Care.
I see it now, looks like a small after hours order, maybe a late market order that was missed. Still don't know about the difference in share 626 vs the 618......
Take Care
I almost pulled the trigger in this one yesterday, then saw where had dropped below a buck a couple times last month, and thought I would see if it would drift lower today.
I am showing it at 1.06 after hours, on 626,211 shares for the day, but the quote from the board shows 1.15 ??????
Thanks again.
THNX SURF.. THIS MUST BE THE REASON FOR REVERSAL IN PPS.
CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
- Significant anti-tumor activity of combination IV belinostat in ovarian cancer reported -
- Oral belinostat demonstrated to be safe and well-tolerated in Phase I -
- Presentation of results from two NCI-sponsored clinical trials -
- CuraGen to provide a clinical update conference call today at 5:00 p.m. Eastern Time -
BRANFORD, Conn., Oct. 25 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that four posters discussing clinical trial results with belinostat were presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA. Data reported included Phase II clinical trial results on intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer, Phase I safety and dose-escalation results for oral belinostat, and data from two NCI-sponsored clinical trials including Phase II results evaluating intravenous belinostat monotherapy for the treatment of ovarian cancers and Phase I results of belinostat in combination with bortezomib for advanced tumors.
CLN-8: Phase II Multicenter Trial of Belinostat (PXD101) in Combination with Carboplatin and Paclitaxel (BelCaP) for Patients with Relapsed Ovarian Cancer
Phase II results for CLN-8 were presented by Neil J. Finkler, MD, FACOG, FACS, Investigator and Director of the Gynecologic Oncology Program at Florida Hospital Cancer Institute in Orlando. At the time of the poster presentation, data were available on 23 patients including efficacy data for 16 patients who had available pre- and post-baseline assessments of tumor. The dose regimen (referred to as BelCaP) of intravenous (IV) belinostat 1000 mg/m2/d in combination with carboplatin AUC = 5 and paclitaxel 175 mg/m2, was well- tolerated.
Reduction in tumor size was seen in 15 of 16 patients by radiologic assessment. To date, objective response has been observed in 8 patients, including 2 partial responses confirmed by RECIST and 6 additional responses that are pending radiologic confirmation. At the time of presentation, 13 additional patients have treatment ongoing with continued radiologic assessment of tumor to determine best response. Activity and responses have been observed in patients with platinum sensitive and platinum resistant disease. CuraGen also announced today that trial has reached the target enrollment.
'We are very encouraged by the level of activity we have seen with BelCaP for the treatment of relapsed ovarian cancer, including activity against platinum resistant tumors,' commented Dr. Finkler. 'We look forward to continuing to treat those patients currently on study and further defining the efficacy of BelCaP in the treatment of this disease.'
'The activity of belinostat in preclinical ovarian studies, either alone or in combination with carboplatin and paclitaxel and in platinum sensitive and platinum resistant cell lines, represents some of the most compelling preclinical data we have developed with belinostat and we are pleased to see it translating into potential clinical benefit for patients with relapsed ovarian cancer,' said Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen. 'We look forward to collecting the remaining data in this study and working with our advisors to determine a potential registrational path forward for IV belinostat in the treatment of ovarian cancer.'
NCI-Sponsored Phase II trial Belinostat in Patients with Refractory or Relapsed Platinum Resistant Epithelial Ovarian Tumors (EOC) and Micropapillary/Borderline (LMP) Ovarian Tumors
Data was reported from a Phase II trial evaluating the activity of IV belinostat monotherapy in two ovarian cancer populations that had received up to three prior lines of chemotherapy: patients with Micropapillary/Borderline (LMP) ovarian tumors or patients with refractory or relapsed platinum resistant (progression within 6 months of last platinum treatment) Epithelial Ovarian Tumors (EOC). Primary endpoints of the study were objective response. Secondary endpoints included stable disease rate, survival, tolerability and assessment of molecular changes with therapy. Tumor response was assessed by RECIST and CA-125 criteria every two cycles. This Phase II trial is an open- label study being led by Dr. Amit Oza at Princess Margaret Hospital in Toronto, Canada. The clinical trial is being sponsored by the NCI under a Clinical Trials Agreement with CuraGen for belinostat.
During the poster presentation it was reported that 12 patients with LMP tumors received a median of 4 treatment cycles (range 1 to 13). To date, one LMP patient achieved a partial response (PR), one patient had a CA125 response, nine had SD, and two were not evaluable. Six patients remain on study. Objective responses to belinostat monotherapy were not observed in a heavily pre-treated well-defined platinum-resistant population of patients with EOC. Belinostat was safe and generally well-tolerated in these two ovarian cancer populations.
Dr. Shannon further commented, 'We are very encouraged by the level of activity reported with IV belinostat monotherapy against these types of ovarian cancer. We believe that these results support and complement the CuraGen BelCaP activity data in relapsed ovarian cancer.'
CLN-9: A Phase I Study of Oral Belinostat (PXD101) in Patients with Advanced Solid Tumors
Initial clinical trial results from the ongoing Phase I study evaluating oral belinostat for the treatment of solid tumors were presented by Dr. Rhoda Molife and Dr. Jooern Ang, investigators at the Royal Marsden Hospital, Sutton, United Kingdom. The Phase I trial is being led by Dr. W. Kevin Kelly, Associate Professor of Medicine in the Section of Medical Oncology and head of The Prostate & Urologic Oncology Program at the Yale Cancer Center, New Haven, CT.
The Phase I study is an open-label, multi-center dose-escalation trial designed to establish the maximum tolerated dose (MTD) for oral belinostat administered once or twice daily in one of two regimens (either continuous daily dosing or dosing days one through 14 in a 21-day cycle). Primary objectives for the study include evaluation of the safety, tolerability and pharmacokinetics of oral belinostat. Secondary objectives include assessment of the pharmacokinetic profile of oral belinostat administered once or twice daily at various dose levels and evaluation of anti-tumor activity. Comprehensive serial ECGs to evaluate the effect of belinostat on QTc interval were also performed.
At the time of the poster presentation, data were available on 60 patients enrolled into the dose-escalation study with 46 patients on the continuous daily regimen and 14 patients dosed days one through 14 in a 21-day cycle. Patients received a median of two treatment cycles (range 1 - 11) with fifteen patients ongoing. The most frequent adverse events reported were fatigue, anorexia and nausea. More than 2400 ECGs were collected in this trial, with no grade 3 or 4 QTc changes noted.
During the study, 15 patients (25%) achieved SD for greater than or equal to 12 weeks, with no RECIST-defined objective responses currently reported. Dose-escalation performed with 250 mg capsules of oral belinostat resulted in a presumptive continuous dosing MTD of 250 mg twice daily. The MTD for dosing of oral belinostat on days one through 14 in a 21-day cycle has not yet been reached. The investigators concluded that oral belinostat has been safe and well-tolerated at doses that may provide flexibility to complement the intravenous formulation of belinostat which is currently in Phase II development.
NCI-sponsored Phase I trial of Belinostat in Combination with Bortezomib in Patients with Advanced Solid Tumors and Lymphoma
Data on 17 patients, of which 14 were evaluable, were reported from this ongoing dose-escalation trial. The primary objective of the trial was evaluation of the safety profile and determination of the MTD of belinostat in combination with bortezomib for patients with advanced solid tumors or lymphomas, which are refractory to standard therapies or for which no standard treatment exists. Secondary endpoints included pharmacokinetics (PK), biological markers and anti-tumor activity. This Phase I trial is an open- label, dose-escalation study being led by Dr. S. Gail Eckhardt, Director of the Developmental Therapeutics and GI Malignancies Programs and Professor of Medicine at the University of Colorado Health Sciences Center. This trial is being sponsored by the NCI under a CTA with CuraGen for belinostat, and under a Cooperative Research and Development Agreement (CRADA) with Millennium Pharmaceuticals Inc. for bortezomib.
The investigators concluded that intravenous belinostat and bortezomib were well tolerated in combination at doses up to 600 mg/m2 belinostat and 1.3 mg/m2 bortezomib, with ongoing enrollment of patients into this dosing cohort. Activity of the combination reported included one patient with Ewing's Sarcoma that has maintained SD for 4 cycles, and two patients, one with peritoneal and one with appendiceal carcinoma, that have maintained SD for 3 cycles. Adverse events were generally grades 1-2 and reversible. No grade 4 non-hematologic toxicities were reported.
Reprints of the poster presentations will be made available on CuraGen's website at http://www.curagen.com or by emailing info@curagen.com
Conference Call Details and Dial-in Information
Date: Thursday, October 25, 2007
Time: 5:00 p.m. Eastern time
Dial-in: 877-272-5391 (domestic)
706-758-4315 (international)
Passcode: 21928842
Webcast: Access to the live webcast and presentation are available at
http://www.curagen.com
A replay of the conference call will be available starting at 8:00 p.m. Eastern time on Thursday, October 25, 2007 through Sunday, November 25, 2007 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 21928842. An archive of the webcast will also be accessible at http://www.curagen.com.
About Belinostat
Belinostat is a small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.
Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal, and ovarian cancers, either alone or in combination with anti- cancer therapies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.
About CuraGen
CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.
About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene(TM) is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to http://www.topotarget.com.
Safe Harbor
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's belinostat programs, including the results of its Phase I and Phase II clinical trials, the quality of data from such trials, the clinical benefits to patients and the potential for future registration and commercialization may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as 'anticipate,' 'believe,' 'could,' 'could increase the likelihood,' 'estimate,' 'expect,' 'intend,' 'is planned,' 'may,' 'should,' 'will,' 'will enable,' 'would be expected,' 'look forward,' 'may provide,' 'would' or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission under the section 'Risk Factors,' as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Glenn Schulman, PharmD
Director of Investor Relations
gschulman@curagen.com
(888) 436-6642
CRGN-P
SOURCE CuraGen Corporation
Source: PR Newswire (October 25, 2007 - 4:00 PM EDT)
News by QuoteMedia
www.quotemedia.com
CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
Wednesday October 24, 4:05 pm ET
- Initial clinical trial results suggesting safety and clinical activity of CR011-vcMMAE reported at the AACR-NCI-EORTC International Conference -
BRANFORD, Conn., Oct. 24 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that the first Phase I clinical trial results on CR011- vcMMAE, an antibody-drug conjugate (ADC) being developed for the treatment of metastatic melanoma, were presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA. To date, 25 patients with unresectable Stage III or IV malignant melanoma have been treated with CR011-vcMMAE in the Phase I dose-escalation portion of the trial.
Results from the ongoing trial suggest the CR011-vcMMAE is well-tolerated at doses up through 1.88 mg/kg with no dose-limiting toxicities noted. Dose- escalation continues with patients currently being enrolled into the 2.63 mg/kg cohort. Of the 25 patients treated with doses ranging from 0.03 mg/kg to 1.88 mg/kg, six patients achieved stable disease lasting up to 11 cycles, and four of the six patients demonstrated tumor shrinkage of up to 20%. Reversible neutropenia was the only drug-related Grade 3 or 4 adverse event, and appears to be dose-dependent. Evaluation of the pharmacokinetic results also suggest that CR011-vcMMAE can be given safely to achieve human plasma concentrations in the anticipated range of activity based on data from in vivo xenograft animal models.
Upon establishing the maximum tolerated dose (MTD), the trial is expected to expand directly into a Phase II study to further assess the activity of CR011-vcMMAE in up to 32 patients with Stage III or Stage IV malignant melanoma.
"We are encouraged by these initial clinical results on CR011-vcMMAE and the suggestion of potential anti-cancer activity in patients with previously progressive disease, which support continued evaluation of this antibody-drug conjugate in the treatment of advanced melanoma. We continue to enroll patients into the trial, and look forward to further characterizing the activity of this novel therapeutic," commented Dr. Mario Sznol, co-Principal Investigator, Co-Director of the Melanoma Program at the Yale Cancer Center in New Haven, CT.
This open-label, dose-escalation study conducted at the Yale Cancer Center, New Haven, CT, MD Anderson Cancer Center, Houston, TX, and The Angeles Clinic and Research Institute, Santa Monica, CA, is evaluating the safety, tolerability and pharmacokinetics of CR011-vcMMAE for patients with unresectable Stage III or Stage IV melanoma who have failed no more than one prior line of cytotoxic therapy. The first part of the trial will evaluate cohorts of patients receiving increasing doses of CR011-vcMMAE to determine the MTD. After determination of the MTD, up to approximately 32 additional patients will be enrolled and treated at the MTD to further define the safety and efficacy of CR011-vcMMAE.
CuraGen will host a conference call on Thursday, October 25, 2007 at 5:00 p.m. Eastern time to discuss these Phase I results on CR011-vcMMAE and the four posters discussing Phase I and Phase II clinical trial results with belinostat being presented at the AACR-NCI-EORTC International Conference.
Conference Call Details and Dial-in Information
Date: Thursday, October 25, 2007
Time: 5:00 p.m. Eastern time
Dial-in: 877-272-5391 (domestic)
706-758-4315 (international)
Passcode: 21928842
Webcast: Access to the live webcast and presentation are available at
http://www.curagen.com
A replay of the conference call will be available starting at 8:00 p.m. Eastern time on Thursday, October 25, 2007 through Sunday, November 25, 2007 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 21928842. An archive of the webcast will also be accessible at http://www.curagen.com.
Reprints of the poster presentation will be made available on CuraGen's website at http://www.curagen.com or by emailing info@curagen.com.
About CR011-vcMMAE
CR011-vcMMAE is an ADC being developed by CuraGen that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics, Inc. (Nasdaq: SGEN - News). The ADC is designed to be stable in the bloodstream. Following intravenous administration, CR011-vcMMAE targets and binds to GPNMB, a specific protein that is predominantly expressed on the surface of melanoma cells. Upon internalization into the targeted cell, CR011- vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. Preclinical studies conducted with this potential therapeutic demonstrate that CR011-vcMMAE produces strong, reproducible and durable effects against tumors in animal models of melanoma. CR011-vcMMAE is currently in a Phase I/II trial initially assessing the safety and identifying a dose to be further evaluated in the Phase II portion of the study.
About Melanoma
Melanoma is a very serious form of skin cancer that accounts for the majority of skin-cancer related deaths each year. The number of people diagnosed with melanoma is rapidly increasing with more than 62,000 new cases expected to be diagnosed in the U.S. during 2007. While the chance of developing melanoma increases with age, it remains one of the most common cancers in young adults. This type of cancer begins in specific cells in the skin and can metastasize, or spread, throughout the body to many organ systems. Patients with Stage IV metastatic melanoma typically have a median survival of less than nine months despite current standard therapies, underscoring the need for novel therapeutics to address the unmet medical need in this patient population.
About CuraGen
CuraGen Corporation (Nasdaq: CRGN - News) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.
Safe Harbor
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's CR011-vcMMAE program, including the potential of CR011-vcMMAE for metastatic melanoma and the progress and timeframe of clinical trials of CR011-vcMMAE may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CRGN-P
Contacts:
Glenn Schulman, PharmD
Director of Investor Relations
gschulman@curagen.com
(888) 436-6642
Source: CuraGen Corporation
thx again ; Very helpful historical analysis; added you to my favorite local historian link!
Hello mlkr, I don't exactly know, but I got all they had offered pre-market at 1.00, which was 2100 shares, and then I had an order in for 5000 at .92, but I don't remember how many actually went through, so somewhere between those two prices, not much, very small trade, sold in the first minute. I have done a lot of trading lately.
Surf has done great work not just here on CRGN, but on over 150+ other boards as well, imho he will likely make another good decision here, but he would be the first to tell you to own a basket of these type stocks, and has posted so many times.
As for as Cortex goes, I just published this over on that board last night and if you had bought it at/near the Calendar year low, you would have done really well, in any of the last 12 years.
Problem of course, is, is are we at that low?
Buying Cortex At The Yearly Low
Patco, Thanks and whew, I thought I had missed something.
This is why I keep saying I think COR is a screaming buy right now. It is because of their 12 months cash before even worrying about an estimated 6 month reserve of cash.
Cor has been VERY resilient over the years, I feel like I know it like the back of my hand, not the technology, but the share price action and how great they are about coming out with new mousetraps, and how humans will pile in when they think they can profit from it.
I put a list together showing a year by CALENDAR year low, starting in Sept. 1995, (this is as far back as my google chart would go on “max”,) and the highest price Cortex reached within the following 12 months.
The first Date/Price is the lowest reported price for each Calendar year, followed by the highest reported price within the following 12 months. (note I think google uses week end, or some measurement because it only reports 2.97 for 2007 high, when we all know it was over 3 for a least a day)
IMHO we are within a few months, or may have already hit 2007’s low, (I am thinking it may drift lower on low volume, but who knows, so I have been building a position in case it goes up from here.)
Of course few are going to buy at the EXACT low, or sell at the EXACT high, but Cortex has been very profitable to those that can stomach the heartaches, grit their teeth, buy/add when perceiving a yearly low, and selling on the pops. I put my money where my big mouth is, and I am hoping to profit from Cortex going forward, should they be able to continue this pattern.
Obviously, on most of these yearly lows, investors did not think highly of Cortex, some likely thought they were going under, management sucked, you name it. Not unlike the current environment imho........
Nov. 95= 2.75, Feb. 96 = 7.25 3 months +4.50 share
Oct. 96 = 2.62, Nov. 96 = 5.12 1 month. +2.50 share
Dec 97 = 1.68, May 98 = 2.43 5 months. +0.75 share
Nov 98 = .375, June 99 = 1.20 7 months +0.83 share
Apr 99 = .281, Mar 00 = 6.68 11 months +6.40 share
Jan 00 = 1.34, Mar 00 = 6.68 2 months +5.34 share
Apr 01 = 1.62, May 01 = 3.21 1 month +1.59 share
Dec 02 = .60, Sept 03 = 4.47 9 months +3.86 Share
Mar 03 = .61, Sept 03 = 4.47 7 months +3.85 share
Aug 04 = 1.65, Jan 05 = 2.85 5 months +1.20 share
Apr 05 = 1.07, Mar 06 = 5.50 11 months +4.43 share
Dec 06 = 1.25, May 07 = 2.97 5 months +1.72 share
Going back 12 YEARS COR produced OUTSTANDING results for those buying/adding at, or near, the yearly low.
I am tired tonight so I may have messed up a number or two, but I think I got them all up there correctly.
Anyway, take care and fun with those cars……
CRGN vs COR
sort of new ..
i ve got some ammunition to put in only one.. Which one is "better"?
tia
GL2A
If I may your average prior to sell?
tia
I saw that 141 million in cash and 110 million in debt. Leaves 31 million positive. Also saw 2.43 cash/share, but no shares published where I looked, so I just divided the 141 million by 2.43 and got near 58 million shares with 31 million cash after debt. Not bad, but I don't know their burn rate.
Like I said I don't know CRGN well enough, but you certainly have called it correctly a bunch of times.
I do know COR pretty well, at least I have never lost money in it, in over 15+ years, although I have had to hold it a while before I sold a few times. I can't even count the times I've owned it. This year I have booked approx 49% profit on COR before this mornings buying spree. I bought a good bunch at 1.14 early this year and sold at 1.70. Maybe this time the odds will catch up to me.
Cor has 18 or so million cash, just did a pipe, near 0 debt, and a fairly slow burn rate and other products to push in their pipeline.
Anyway, thanks again and good luck to both of us!
CRGN had $100 million in long tern debt, but CRGN has $2.40 in cash per share. COR has less than .40 per share and may have more problems rebounding.
Likely another good call, I don't know the company well enough to hang and got out. I have been buying COR all morning however.
I'm betting we will end the day with an Bullish Engulfing Pattern (CRGN) and have a positive day on Friday. I have been buying on weakness below .95 all morning.
sold at the open for 1.04, huge volume in first minute....
CRGN just dropped to .92, so I picked up some more. Interesting morning.
GLTU
I bought a little Cor under a buck as well, 18 million in the bank, a little over a million/mo burn rate, and plenty of time to "push" other pipeline candidates, which they have.
Just bought some CRGN at $1, only because of the low volume.
I bought the 2100 shares they had at 1.00 even, of course cheaper now.
Cor is getting hammered as well this am, so I am looking to get back in over there as well. Been in and out of that one for 15-17 years.
Just saw CRGN, down big on little volume, may place a pre-market order. Trading these stocks can sometimes be luck(sold my last block yesterday, so I'll will be a buyer today)
At some point this will become a buy again, any idea of the downside?
CuraGen Drug Fails Midstage Study
Thursday October 11, 7:41 am ET
CuraGen Drug for Cancer Treatment Side Effect Fails Midstage Study, Program Discontinued
BRANFORD, Conn. (AP) -- Biotechnology company CuraGen Corp. said Thursday its drug candidate velafermin, aimed at preventing mouth ulcerations in cancer patients, failed in a midstage study and that it's discontinuing its development.
The drug was being tested as a treatment to prevent oral mucositis, a condition in patients undergoing chemotherapy treatment. The lining of the throat become damaged by the treatment and ulcers can form.
Based on the Phase II clinical trial results, the company said it will discontinue the drug's development. It will focus on developing belinostat, aimed at treating solid tumors and malignancies. That drug candidate is now in Phase II clinical trials.
Shares of CuraGen fell 14 cents, or 9.7 percent, to $1.31 in premarket trading.
http://biz.yahoo.com/ap/071011/curagen_study.html?.v=1
I missed what is going on this morning, just see it at a buck pre market. Ouch and sorry for the longs.
I chickened out and was one of the sellers near the low the other day at 1.37 a .20 point haircut from my most recent purchase.
When I read you first post, I just figured I was one of those ones that sold out too early.....
sheesh, time to bend over and take it.
another good day...tuesday's dip was bought big. I mentioned that the CMF actually went up for the day, accumulation/distribution did too. don't let the big red volume bar fool you (me), a big player is playing by his own rules. The arroon spells it all out...the trend is intact.
http://stockcharts.com/h-sc/ui?s=CRGN&p=D&yr=0&mn=9&dy=0&id=p29206020256
think it was coincidence they issued this update when they did (august 6th after the stock bottomed out at 1.08)?
just crossed my eyes and looked at the chart sideways a few minutes ago. just noticed yesterday's spike down effectively made it doublebottomish, and a test of the 50sma at the same time. the ugly spot is the volume. the market maker was doing something fishy yesterday. I don't beleieve there really was a 2.6million share transaction that didn't move the pps at all. Am I supposed to believe the pps traded down and back up over a 10cent range in the morning, on a few hundred thousand shares and then 2.6 million go in a minute with no change in the pps? I think a ton of buying was going on on the way up from 1.35 and it was tallied and transacted at 3pm. I think it was a ploy to shake weak hands...now there is a big red volume bar, since the hammer didn't finish green. I expect a big up day smashing through 1.57-1.50 soon.
Also, despite the red close, the CMF actually had an uptick yesterday.
Yikes, I guess that gym g nailed it that folks are taking/giving up positions waiting on this news:
"We look forward to reporting top-line efficacy and safety results in mid-October, which we hope will confirm the data observed previously with 30 mcg/kg velafermin in our first Phase II trial for the prevention of severe OM."
http://biz.yahoo.com/prnews/070806/nem096.html?.v=10
Hammer Patterns (CRGN)
Bullish signal for CRGN today, this one doesn't want to get up the bullishness trend yet!
I was on a trip to San Fran and just returned! The CRGN chart has lost some steam and I may take some of today myself(just waiting to see how it trades today) Good to be back looking into stocks, missed a big event on Friday(jobs numbers)
Thanks for that gym g, I had missed that one. That may help explain the recent strength.
I am going to update that link...that calendar is only as good as we make it!
I'm still here, on the road, not able to check anything but looks like things are going well.
I tried to post a response to you about CRGN's timeline for events on Monday but ran out of time.
It was on Yahoo, august 6th PR:
http://biz.yahoo.com/prnews/070806/nem096.html?.v=10
CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
Monday August 6, 4:15 pm ET
- Enrollment completed in Phase II trial evaluating a single dose of velafermin for the prevention of severe oral mucositis -
- Continued focus to define registrational path for belinostat in the treatment of cancer -
- Conference call and webcast to be held today at 6:00 p.m. Eastern Time -
Velafermin for the prevention of severe oral mucositis (OM):
Enrollment has been completed in the Phase II randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single infusion of velafermin for the prevention of severe OM. A total of 390 patients at 33 centers were enrolled throughout the United States. Primary safety and efficacy assessments of treated patients will be concluded at participating centers during August with preliminary, top-line efficacy results from the completed trial available in mid-October of 2007. Patients will be followed for an additional year to assess long term outcome with results available during the fourth quarter of 2008. The Phase II trial is designed to assess the reduction in the incidence of severe WHO Grade 3 or 4 OM in patients receiving high-dose chemotherapy, with or without total body irradiation (TBI), prior to autologous bone marrow transplantation (BMT). Patients enrolled in the trial were randomized to receive a single infusion of either placebo or one of three doses of velafermin (10 mcg/kg, 30 mcg/kg or 60 mcg/kg) administered 24 hours after BMT.
"We believe that the ability to recruit nearly 400 patients in 13 months speaks to the unmet need in the severe OM market, and feel there is a substantial opportunity for a product like velafermin, which could provide a convenient single dose regimen for the prevention of severe OM," commented Dr. Shannon. "We look forward to reporting top-line efficacy and safety results in mid-October, which we hope will confirm the data observed previously with 30 mcg/kg velafermin in our first Phase II trial for the prevention of severe OM."
Hello Surf, I was wondering what you are thinking about the current chart for CRGN as it sits just below that 1.57 mark for the second consecutive close? It seems relatively strong in here to me, but I value your opinion and was hoping to get your thoughts.
Hope you are on an extended "surfing" weekend, and thanks again!
CRGN is just a penny away from breaking its recent high and then breaking out to a new trading level/range.
CCI Buy Signals (CRGN)
I don't believe there is any near term event for CRGN, if there was these guys are tracking it(chart looks good)
Posted by: DewDiligence
In reply to: Aiming4 who wrote msg# 52605
Date:9/24/2007 10:01:47 PM
Post #of 53069
Clinical / Regulatory / Litigation Calendar
[Please keep entries up to date! See updating procedure at the end of this post.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: IDIX (fix error re Tyzeka vs Baraclude trial); IMCL (removed entry—CAIRO2 data out); SNUS (removed entry—TocP data out); VRTX (update re AASLD).
ACHN – See GILD
AMLN – Phase-3 LAR results: 2H07; Byetta monotherapy results any day.
ANOR / AOM.TO – pivotal AMD3100 results any day.
COR – CX717 IND for ADHD IIb trial received by FDA psychiatry division on 9/11/2007, decision due within 30 days.
CRME - IV version of RSD1235: FDA advisory panel 12/11/07.
CYT.TO - Initiated pivotal A-fib trial Oct/06. Complete enrollment 2nd/half 07. Results 2nd half 08.
DDSS – Tramadol NDA: second approvable letter received 5/31/07. New clinical trial likely.
DNA – Avastin sBLA in breast cancer action date: 2/08; Avastin adjuvant CRC interim look Q4 07; Rituxan in Primary Progressive MS Ph III Results Q1 08.
DNDN – Provenge 9902b study: interim analysis (~180 deaths) 2H08; final analysis (360 deaths) 2010.
DORB – OrBec NDA in GVHD: FDA action date was extended in July to 10/21/07.
ELN- Tysabri PDUFA date for Chron's disease 10/15/07
AAB-001 Phase III start in Alzheimer's Disease Q4 07
GILD – Viread NDA submission for HBV: 4Q07.
GILD – GS9190 polymerase inhibitor for HCV: data from phase-1: 3Q07.
GPCB – Satraplatin SPARC trial final OS data: late 2007. (FDA NDA based on PFS data was withdrawn.)
GTCB – ATryn phase-3 for HD in US: report data 4Q07, submit BLA 1Q08.
GTCB – ATryn phase-2 DIC trial by Leo Pharma in Europe/Canada: enrollment complete mid 2008. (First patient enrolled 8/6/07.)
GTCB – Merrimack MM-093: results of phase-2 extension trial in RA: late 2007.
GTOP – Final MyVax results Dec 07.
IDIX – Tyzeka vs Baraclude phase-4 (12 weeks PK): report data 3Q08.
IDIX – Tyzeka ph3 data in decompensated liver disease: enrollment completed 1Q07, reporting date unknown.
IDIX – IDX899 in HIV: Phase-1b monotherapy in treatment-naïve patients (7 days): start dosing Oct 2007; report preliminary results Dec 2007; report full results Feb 2008 at CROI conference. Phase-2 in combination with SoC therapy: begin recruitment in 2008.
IDIX – IDX102/IDX184, 2nd generation HCV nucleosides: submit IND 4Q07.
ISA.TO-European psoriasis P3 results 2008. Phase 2B 6&12 month renal results 2008. Phase II/III Uveitis results 2008.
ITMN – ITMN-191 Phase-1B Start dosing 9/07. Initial PK data from perhaps 1st 3 cohorts: Q1 2008
ITMN - Pirfenidone - CAPACITY Trials enrollment completed May 2007. Top-line results Late 2008 (72 week treatment period). No interim analysis planned, though monitored for safety.
JNJ – TMC125 for HIV: FDA action date 1/18/08.
LBPFF – see DDSS
MCU/MPH.to - Medicure - MC-1 Lead drug candidate for cardiovascular reperfusion is in PH 3 trial /w 3000 patients.
Expect full enrollment Nov/07 with Data by August /08.
Medivir – ph-1 TMC453350 results in HCV at AASLD 11//07.
Merrimack: see GTCB
MS.TO - Complete enrollment in pivotal Secondary Progressive MS trial this year, interim results mid 2008, trial results in 2009.
NBIX - Indiplon IR PDUFA date December 12, 2007
NBIX - Indiplon IR Product launch, indiplon IR 1Q08
NBIX - NBI-56418 Complete enrollment, 6-month phase 2b endometriosis trial 4Q07
NBIX - NBI-56418 Topline data, 6-month phase 2b endometriosis trial 2Q08
Novocell – see SRDX
NRMX, NRM.TO – European ph-3 Alzhemed trial complete 2008 (N Amer ph-3 failed, as reported 8/26/07).
PHRM – Satraplatin MAA to EMEA to be filed 2/08 following analysis of final OS data.
PPHM -
Bavituximab (anti-viral): phase 1B HCV top-line info released 3/07. Final data at AALSD Nov.
Bavituximab (anti-viral): phase 1 trial in HCV/HIV coinfected patients initiated 7/07.
Bavituximab (anti-cancer): phase 2 breast cancer trial protocol submitted to reg. board 9/07
Bavituximab (anti-cancer): phase 2 lung cancer trial protocol submitted to reg. board 7/07
Bavituximab (anti-cancer): phase 1B solid tumor top-line info released 5/07.
Cotara: phase 2 glioblastoma multiforme Indian trial patient enrollment initiated 6/07.
Cotara: glioblastoma multiforme US trial sites expanded to include MUSC 6/07.
RPRX– Proellex
*Initiate US PII Endometriosis trial (Enrollment Oct 2007)
*One year extension data (Q1 2008)
*Initiate Fibroids Pivotal PIII trials (YE2007)
*Initiate Anemia Pivotal PIII trial(s) (YE2007)
RPRX – Androxal
*FDA Androxal PIII meeting: Oct 15; PR expected 15-31 Oct 2007
*Initiate Pivotal PIII trials (Q4 2007)
RPRX – Other: select alternate Proellex-class compound for advancement into breast cancer studies via potential partner TBA.
SGP – Ph-2 data for SCH 503034 in HCV: 2H07
SPPI – See GPCB.
SRDX - Novocell phase-1/2 trial in type-1 diabetes: late summer 2007 (enrollment complete 8/30/06).
SYMD- Synthemed-Circulatory System Devices Advisory Panel has been scheduled for September 19, 2007 for Repel CV.
TH.TO -Complete enrollment confirmatory TH9507 HIV Associated Lipodystropy trial 3rd qtr/07, final results 1st qtr/08.
UTHR - Viveta (Inhaled Treprostinil for PAH). July 13, 2007 enrollment closed with 235 enrolled. October 5th last patient out +/- 1 week. Early November around AHA top-line results
UTHR - OvaRex. 6/06 IMPACT II completed enrollment. Unblind when 118 recurrences reached in both IMPACT I and II. As of 6/30/07 number of recurrences: IMPACT I-128 IMPACT II-112.
UTHR - Oral Treprostinil (FREEDOM-C). 16 week combination study. Interim analysis possible at 150 (targeting to enroll 300). Enrollment as of 7/30/07 was 115.
UTHR - Oral Treprostinil (FREEDOM-M). 12 week monotherapy study. Interim analysis possible at 90 (targeting to enroll 150). Enrollment as of 7/30/07 was 62.
VRTX – Telaprevir SVR data from PROVE-1 and PROVE-2 at AASLD (11/5/07). The PROVE-1 data will be final, and the PROVE-2 data may be final.
VRUS – Ph-3 Clevudine for HBV: start phase-3 3Q07. Ph-1 R7128 in HCV full data at AASLD (top-line data were reported 9/10/07). New study of R7128 with pegifn and riba: start 4Q07, rpt data at EASL 4/08.
ZGEN – rThrombin FDA response date: 1/17/08 (was extended by 3 months.).
--
Procedure For Updating Clinical-Trials List
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old list. You can find a pointer to this list in the iBox at the top of the main message-board screen.
2. Make your additions or modifications, inserting any new items in alphabetical order.
3. Post the updated text in a new message in reply to the message with the old list.
the CRGN website says 3rd quarter but I swear I read somewhere that results would be October:
http://www.curagen.com/get_prod.php?prod_id=1
it is starting to make sense now...the pps strength at the end of september might have been unwarry buyers that were expecting a q3 result. I SWEAR I read somewhere they would be mid october. So the buyers for a september pr might have been the sellers these last few days. especially note the dump (and recovery) CRGN took midday friday:
http://finance.yahoo.com/q/bc?s=CRGN&t=5d&l=on&z=m&q=l&c=
What news are you referring too? The chart looks solid and I have bought more on every drop the past week.
surf
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
158
|
Created
|
04/12/01
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |